Literature DB >> 21419529

Outcome of patients with amyotrophic lateral sclerosis attending in a multidisciplinary care unit.

F J Rodríguez de Rivera1, C Oreja Guevara, I Sanz Gallego, B San José Valiente, A Santiago Recuerda, M A Gómez Mendieta, J Arpa, E Díez Tejedor.   

Abstract

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a disease with very poor prognosis, and a mortality of 50% at 18 months after diagnosis. Multidisciplinary units attempt to improve the quality of life and survival of patients with ALS. The aim of this study is to evaluate every 3 months, over a 24-month period, the outcome of patients treated at the ALS unit since the time of diagnosis.
MATERIAL AND METHODS: We performed a prospective observational study of patients treated in the ALS unit following a clinical pathway since the time of diagnosis with quarterly reviews from 2006 to 2010. The age of onset, functional impairment (ALSFRS-r), impairment of respiratory function, dysphagia and signs of depression and/or cognitive impairment were evaluated in relation to the initial location symptoms (bulbar [B], upper limbs [UL], lower limbs [LL]).
RESULTS: A total of 42 patients (30 males and 12 females) were evaluated (mean age at onset of 57.97 years old, SD 14.56). There was an even distribution by location of onset of symptoms (B 14 patients, UL 14, LL 14.) Functional impairment (B -26,89 points, UL -22,48 points, LL -22,66 points), the need for use of BIPAP (B 64.28%; UL 35.71%; LL 50%), the presence of dysphagia (B 85.71; UL 42.85; LL 71.42%), signs of depression (B 78.57%; UL 35.71%; LL 64.28%) and cognitive impairment (B 42.85%; UL 21.42; LL 35.71%) was higher at 24 months of progression in patients with bulbar onset. There was no difference in mortality data (23.80% overall).
CONCLUSIONS: The treatment in multidisciplinary units does not change the neurological progression of the disease, but increases the survival of ALS patients regardless of their initial onset, emphasising the use of multidisciplinary care.
Copyright © 2010 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21419529     DOI: 10.1016/j.nrl.2011.01.021

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  4 in total

Review 1.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  Trends in Research Literature Describing Dysphagia in Motor Neuron Diseases (MND): A Scoping Review.

Authors:  Ashley A Waito; Teresa J Valenzano; Melanie Peladeau-Pigeon; Catriona M Steele
Journal:  Dysphagia       Date:  2017-06-29       Impact factor: 3.438

3.  New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

Authors:  James D Berry; Merit E Cudkowicz
Journal:  Clin Investig (Lond)       Date:  2011-10

Review 4.  Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology.

Authors:  Robert G Miller; Benjamin Rix Brooks; Rebecca J Swain-Eng; Robert C Basner; Gregory T Carter; Patricia Casey; Adam B Cohen; Richard Dubinsky; Dallas Forshew; Carlayne E Jackson; Ed Kasarskis; Nicholas J Procaccini; Mohammed Sanjak; Fredrik P Tolin
Journal:  Neurology       Date:  2013-11-22       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.